Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating the EuroHeart program, an observational and prospective multicenter initiative designed to improve quality of care for patients with common cardiovascular diseases such as Acute Coronary Syndrome ACS, heart failure, and atrial fibrillation. EuroHeart collects standardized and harmonized patient data to support continuous quality improvement by monitoring adherence to quality indicators defined by the European Society of Cardiology ESC. The program aims to understand how well proven treatments are applied in everyday clinical practice. The study involves continuous data collection from consecutive patients hospitalized or treated for these cardiovascular conditions. Participants enter a 12-month follow-up period during which clinical events and health status data are gathered. This registry specifically evaluates adherence to ESC quality indicators in Italian clinical practice, including measures such as time to reperfusion and prescription of recommended medications at discharge. Participants will be monitored through regular collection of clinical data over the 12 months following enrollment. Researchers will assess adherence to multiple ESC quality indicators related to treatment and management of STEMI and NSTEMI patients, including evaluations of left ventricular function, lipid levels, and use of dual antiplatelet therapy and other medications. The study also tracks cardiovascular and non-cardiovascular events during follow-up to support quality improvement efforts. Participation involves consent and data collection without experimental treatments.
Actively Recruiting
Researchers are studying patients experiencing arrhythmic storm, a serious heart condition characterized by frequent and sustained ventricular arrhythmias that do not respond to standard antiarrhythmic drugs. This international multicenter observational study aims to evaluate the safety and effectiveness of Percutaneous Stellate Ganglion Block PSGB in reducing arrhythmic relapses in such emergency cases. The study is coordinated by Fondazione IRCCS Policlinico San Matteo of Pavia, Italy, and addresses a gap in large-scale data on this procedure. Participants who meet the criteria will receive PSGB using either the anatomical or echo-guided approach. Depending on patient needs, the procedure may involve a single anesthetic injection or continuous anesthetic infusion via a catheter connected to a pump. The study compares the number of arrhythmic events and defibrillations before and after PSGB treatment and notes any complications occurring within 12 hours post-procedure. During participation, patients will be monitored closely for arrhythmic relapses using defibrillation counts and anti-tachycardia pacing data. Complications such as hematomas, vascular injuries, and nerve damage will be recorded. Data are collected using a secure electronic system, with effectiveness measured by arrhythmic event reduction in the 12 hours following PSGB compared to the 12 hours prior. The study plans to enroll patients over several years with ongoing safety and outcome evaluations.
Actively Recruiting
Researchers are evaluating clinical outcomes and safety in patients diagnosed with advanced high-grade ovarian cancer, focusing on how the tumors homologous recombination HR status affects treatment responses. This observational study involves two patient groups based on HR status, aiming to understand the impact of matched therapies in a real-world setting from January 2021 to January 2026. Patients are divided into two cohorts Cohort A includes those with homologous recombination deficient HRD ovarian cancer treated with Olaparib plus Bevacizumab as maintenance therapies after responding to first-line platinum-based chemotherapy Cohort B includes homologous recombination proficient HRP patients receiving standard clinical care chosen by their doctors. Participants are enrolled either retrospectively if already treated or prospectively if starting first-line therapy, based on tumor HR test results. During the study, researchers will monitor clinical outcomes and safety for up to three years after enrollment. Data collection includes treatment details, responses, and adverse events to evaluate therapy effects in each group. Participants provide informed consent and remain under regular care, with outcomes tracked to understand the real-world effectiveness and safety of targeted therapies for advanced ovarian cancer.
Actively Recruiting
Aromatic L-amino acid decarboxylase deficiency AADC-D is a rare genetic condition that affects brain chemicals and can cause serious neurological and developmental issues in newborns. Early diagnosis is important to allow timely specialist care and evaluation for treatment options such as gene therapy. This study aims to develop a newborn screening program for AADC-D in the Liguria region of Italy and estimate how often the disease occurs in this population. The study will include about 16,000 newborns born in participating hospitals. After parents or legal caregivers give consent, blood samples will be collected using dried blood spot cards as part of the existing newborn screening routine. These samples will be tested with tandem mass spectrometry to measure 3-O-methyldopa 3-OMD, a marker that may indicate AADC-D. Samples with positive results will be retested, and if still positive, genetic testing of the DDC gene will confirm the diagnosis. Participants are involved only through the collection of blood samples during routine newborn screening. Researchers will evaluate 3-OMD levels, establish reference and cut-off values for screening, and assess the screening methods performance over two years. The study aims to support a reliable newborn screening program for early detection of AADC-D, enabling prompt identification and care of affected infants.